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Abstract
Background: Transfusion related acute lung injury (TRALI) is a potentially fatal Acute Lung Injury
following transfusion of blood components. Hypotheses implicate donor-derived anti-human
leukocyte antigen or granulocyte antibodies reacting with recipients' leukocytes, releasing
inflammatory mediators. Lack of agreement on underlying cellular and molecular mechanisms
renders improving transfusion safety difficult and expensive.
Case Presentation: Literature search has not revealed any case of TRALI from Pakistan. We
report the case of fatal TRALI in a 68 year old male who received blood products after coronary
artery by-pass surgery.
Conclusion: This article aims to create awareness about this complication and suggests that post
transfusion cardiopulmonary instability should alert to the possibility of TRALI.
Background
TRALI is a potentially fatal complication of transfusion
occurring in 1 per 5000[1]. However, being an under rec-
ognized and under-reported condition, information
about TRALI is mostly patchy and the true global inci-
dence is unknown. To the best of our knowledge, this is
the first ever documented case of TRALI from Pakistan.
Case presentation
A 68-year previously healthy, retired male presented with
inferior wall myocardial infarction. Cardiac catheteriza-
tion revealed critical three-vessel Coronary Artery Disease
(CAD) for which he received streptokinase and was
admitted for Coronary Artery By-pass Graft (CABG) sur-
gery.
His weight was 69 kg, height 162 cm, and he was of Asian
origin. He was a non-smoker with no associated co-mor-
bid conditions. He had a family history of diabetes melli-
tus (father). Pre-operative evaluation included a normal
chest radiograph and unremarkable routine blood chem-
istries.
Surgery was uneventful. Five-vessel CABG was carried out
where patient remained on cardiopulmonary bypass for 1
hour and 45 minutes and was weaned off without ino-
tropic support, with good hemodynamic profiles.
Post-operatively, he remained hemodynamically stable
for 1 hour in intensive care unit, after which he was noted
to have excessive bleeding from his tube which was drain-
ing the mediastinum. Considering platelet dysfunction, as
he was on aspirin previously, six units of random donor
platelets were transfused. Within an hour of transfusion,
he developed hypotension. His oxygen saturation
dropped from 98% to 90%, with PaO2/FiO2 of 180 and
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pulmonary artery pressure of 64/39 mmHg. He developed
small amounts of frothy, proteinaceous appearing pulmo-
nary exudates from the endotracheal tube that required
repeated suctioning. He became increasingly hypotensive
and had to be resuscitated per Advanced Cardiac Life Sup-
port protocols, but he continued to remain hypotensive.
He was rushed to the operating room for exploration of
any correctable cause. Due to his hemodynamic instabil-
ity, he was placed on the heart-lung machine. Doppler
ultrasound revealed all five grafts to be functional. Intra
aortic balloon pump was inserted and trans-esophageal
echocardiography was done to assess left ventricular func-
tion. A left atrial line was also placed. Further, six units of
packed red blood cells were transfused to combat
hemodilution resulting from prolonged second pump
run. Despite of all measures, the patient developed frank
right heart failure.
Attempts to wean off from machine were unsuccessful
and therefore a right ventricular assist device was placed
which allowed him to come off heart-lung machine with
massive inotropic support. He was shifted to intensive
care unit once again but this time in a critical condition
with open chest where he was mechanically ventilated.
His vital signs continued to demonstrate marginal hemo-
dynamics: blood pressure, 40/10 mm Hg; oxygen satura-
tion, 88% and pulmonary capillary wedge pressure 13–14
mm Hg. There was ongoing loss of clear proteinaceous-
appearing fluid from the lungs requiring elevated ventila-
tor parameters to maintain oxygen saturation greater than
90%. The patient continued to desaturate, became
increasingly hypotensive with bradycardia. His cardiac
output continued to drop as central venous pressure
mounted and he could not be resuscitated.
Discussion
TRALI can be caused by transfusion of any blood product
but whole blood-derived platelet concentrates are the
most frequently implicated[2]. Our patient also devel-
oped respiratory distress soon after platelet transfusion.
The risk of TRALI increases if the donor is a multiparous
female[3]. Retrospective inquiry of the donors revealed
that the donor of the first unit of platelets was a multipa-
rous female.
Patients at increased risk of developing TRALI include
those who have hematologic malignancies or underlying
cardiac condition[4]. Our patient had undergone cardiac
surgery, which predisposed him to develop TRALI, but the
exact mechanism underlying this predisposition needs to
be explored. Is it hypoxia at the microscopic level that ini-
tiates the cascade during cardioplegia?
The pathogenesis of TRALI is complex and there is lack of
agreement on any one hypothesis. It can result from both
immune mechanisms such as donor derived anti HLA and
granulocyte antibodies against recipient's leukocytes or
may be non-immune resulting from neutrophil priming
agents such as lysophosphotadylcholines and proteins
like CD40 ligand which are abundant in stored cellular
blood components[5]. The lungs are the main organs
affected by the disorder. The reason is its unique microv-
asculature which allows neutrophils to be sequestered
even under physiological conditions. It has been hypoth-
esized that two distinct events are necessary for TRALI:
first is recent surgery, severe infection or trauma that not
only prime neutrophils but also activate pulmonary
endothelial cells resulting in plugging of pulmonary
microvasculature by more rigid and less pliable neu-
trophils; Second is the transfusion of biologically active
mediators (anti-HLA or anti-granulocyte antibodies),
which activate already primed adherent neutrophils with
consequent endothelial damage and capillary leakage[2].
The age of the transfused platelets, plasma and red cells
was three, seven and eight days respectively, in our case.
These features favor the possibility of both immune and
non immune mechanisms to have occurred in our
patient. Various laboratory tests are available for detection
of antibodies in both patient's and donor sera but the
sophisticated techniques coupled with their low sensitiv-
ity and specificity have failed to popularize them for diag-
nostic purpose and their lack of availability in our setting
refrained us from doing such work up.
Detection of TRALI in a patient is a diagnostic dilemma
and medical personnel should apprehend new onset
Acute Lung Injury (ALI) developing during or within 6
hours of blood transfusion[6]. Clinical signs include rapid
onset of tachypnea, cyanosis, dyspnea, fever and hypoten-
sion. Besides these, certain laboratory criteria need to be
fulfilled for establishing diagnosis of TRALI: PaO2/FiO2 <
300 or pO2 <90% at room air in the absence of impaired
left ventricular function[1]. Our patient had clinical evi-
dence of hypoxemia as lung auscultation revealed diffuse
crackles and decreased breath sounds, while his chest radi-
ographs were characteristic of pulmonary edema. TRALI
also needs to be distinguished from anaphylactic transfu-
sion reactions, protamine reactions and transfusion
related circulatory overload. Thus, the diagnosis of TRALI
is much the matter of skilled clinical judgment, expertise
and awareness of clinicians. The significance of the correct
diagnosis lies in the fact that most of the patients recover
within 24–48 hours without permanent sequel. However,
a variable mortality of 11% to 45% has been reported[7].
There are already various concerns regarding the poor
short and long term outcomes associated with transfusion
of blood products and TRALI associated morbidity and
mortality adds to these concerns. Being an under diag-
nosed condition, these numbers might represent only the
tip of an iceberg.
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Treatment of TRALI is generally supportive and similar to
that for ALI[2]. Aggressive respiratory support, including
supplemental oxygen and mechanical ventilation can be
life saving as was done in our case also, but unfortunately
TRALI proved fatal for him. Other therapeutic measures
include extra corporeal membrane oxygenation and addi-
tional blood component therapy if clearly indicated. The
role of steroids and diuretics that had been previously
used has been questioned. We think that the effects of
low-dose epinephrine or methoxamine on the pulmonary
vasculature and control of blood pressure during and
before the occurrence of lung injury needs to be explored
as this might revolutionize the management of TRALI.
Since mortality resulting from TRALI can be significant,
prevention of the disorder is crucial with the responsibil-
ity resting on blood bank services. Haemovigilance data
from Scandinavia and the UK demonstrates that utilizing
solvent detergent-treated fresh frozen plasma can greatly
minimize TRALI probably by dilution and neutralization
of leukocyte antibodies and removal of cells and cell frag-
ments in pooled plasma[8]. Similarly, eliminating mul-
tiparous females from donating might ensure TRALI
prophylaxis by decreasing HLA and granulocyte antibod-
ies in blood products. relevant information not included
in the case presentation, and put the case in contextor that
explainspecific treatment decisions.
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